| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.94 | $88.07 (0%) | 🛒 Add to cart |
| 60 | $2.52 | $176.14 $151.12 (14%) | 🛒 Add to cart |
| 90 | $2.38
Best per pill | $264.21 $214.17 (19%) | 🛒 Add to cart |
Synonyms | |||
Similar products
More info:
Tizanidine: Effective Muscle Spasticity Management with Favorable Safety Profile
Tizanidine hydrochloride represents one of those interesting pharmaceutical agents that sits right at the intersection between neurology, rehabilitation medicine, and pain management. As a centrally-acting alpha-2 adrenergic receptor agonist, it’s primarily indicated for the management of spasticity, particularly in conditions like multiple sclerosis and spinal cord injury. What makes tizanidine particularly valuable in clinical practice is its unique pharmacological profile – it reduces spasticity without causing significant muscle weakness, which distinguishes it from other antispasticity agents like baclofen or diazepam.
baclofen
Baclofen is a centrally-acting skeletal muscle relaxant that’s been in clinical use for decades, yet remains surprisingly misunderstood in its applications. Originally developed as an antispasticity agent, this GABA-B receptor agonist has found utility far beyond its initial indications. We’ve been using it in our neurology practice since the late 1990s, and I’ve watched its therapeutic profile evolve from a simple muscle relaxant to what I’d consider one of our more versatile neuropharmacological tools.
baclosign
Baclosign represents one of those rare clinical tools that fundamentally changes how we approach spasticity management. When I first encountered the prototype six years ago during a neurology conference, I was skeptical—another muscle monitoring device claiming to revolutionize treatment. But what struck me was the elegant simplicity of combining surface electromyography with motion capture in a wearable format. We’ve since implemented it across our spasticity clinic with remarkable consistency. Baclosign: Advanced Spasticity Monitoring and Treatment Guidance - Evidence-Based Review 1.
ciplox
Ciprofloxacin, commonly encountered in clinical practice as Ciplox, represents a cornerstone fluoroquinolone antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. Its development marked a significant advancement in antimicrobial therapy, particularly for complex infections where older agents failed. We initially saw its potential in hospital-acquired pneumonias and complicated UTIs, but its utility has expanded significantly over the decades. The challenge, as with any potent agent, has always been balancing its remarkable efficacy with a mindful approach to its safety profile, something our team has debated extensively during formulary reviews.
cipro
Ciprofloxacin, commonly referred to by its brand name Cipro, represents a cornerstone in modern antimicrobial therapy. This fluoroquinolone antibiotic has been a workhorse in clinical practice for decades, particularly valued for its broad-spectrum activity against both Gram-positive and Gram-negative bacteria. What makes Cipro truly distinctive isn’t just its antibacterial potency but its unique pharmacokinetic profile that allows for excellent tissue penetration - something we’ve repeatedly observed makes the difference between adequate and exceptional clinical outcomes, especially in difficult-to-treat infections like those involving bone or the prostate.
flexeril
Cyclobenzaprine, marketed as Flexeril, remains one of those workhorse medications in musculoskeletal medicine that somehow never gets the spotlight it deserves. When I first started in sports medicine 15 years ago, we’d throw NSAIDs at every muscle spasm case until someone’s creatinine started creeping up. Then Dr. Chen, my senior partner, tossed me a Flexeril sample and said “Try this next time - just watch the morning drowsiness.” That casual suggestion changed how I managed at least 30% of my acute back pain patients.
lioresal
Baclofen, marketed under the brand name Lioresal among others, is a gamma-aminobutyric acid (GABAB) receptor agonist primarily used as a muscle relaxant and antispastic agent. It’s one of those foundational medications in neurological rehabilitation that every physiatrist and neurologist becomes intimately familiar with, yet we’re still uncovering nuances in its application decades after its introduction. The drug’s journey from laboratory discovery to clinical staple reveals much about how we manage spasticity today.
Luvox: Effective OCD and Depression Treatment - Evidence-Based Review
Fluvoxamine, marketed under the brand name Luvox among others, is a selective serotonin reuptake inhibitor (SSRI) antidepressant primarily used to treat major depressive disorder and obsessive-compulsive disorder. It’s one of those workhorse medications that never made headlines like Prozac but has been quietly effective in countless patients’ lives. The drug works by increasing serotonin levels in the brain, which helps improve mood, reduce anxiety, and decrease obsessive thoughts and compulsive behaviors.
robaxin
Let me walk you through what we’ve learned about Robaxin over the years - not just from the package insert, but from actually using it in practice. When methocarbamol first came across my desk back in residency, I’ll admit I was skeptical. Another muscle relaxant, another promise of relief for those agonizing back spasms that leave patients literally frozen in place. But there was something different about this one - the way it seemed to hit that sweet spot between efficacy and tolerability.